[90y] Yttriumcitrate Cis Bio International

Yttrium (90Y) citrate is a radioactive pharmaceutical used for intraarticular therapy, primarily in synovitis treatment. This sterile solution supports localized radiation for targeted joint relief. Suitable for medical facilities with radiopharmaceutical handling protocols. Short-term storage guidelines apply.

Yttrium (90Y) citrate is used in medical settings to manage synovitis, particularly in joints unresponsive to conventional therapies. It delivers localized radiation to reduce inflammation and pain when injected intraarticularly. This approach is often considered for persistent joint conditions requiring palliative care.

After intraarticular injection, Yttrium (90Y) citrate emits beta radiation to target inflamed synovial tissue. Patients may experience gradual reduction in joint swelling and discomfort over several weeks. The effects are localized, minimizing systemic impact compared to broader treatments.

Handle Yttrium (90Y) citrate with radiation safety protocols, including protective equipment and containment measures. Administer only by trained professionals in licensed facilities. Monitor patients post-injection for radiation exposure and allergic reactions. Follow local regulations for radioactive waste disposal.

No direct drug interactions are reported for Yttrium (90Y) citrate due to its localized administration. However, avoid combining with other intraarticular therapies without medical supervision. Radiation exposure from other sources may require dose adjustments. Consult a radiopharmaceutical specialist for combined treatments.